Aurinia Pharmaceuticals
AUPH
184 hedge funds and large institutions have $533M invested in Aurinia Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 70 increasing their positions, 45 reducing their positions, and 39 closing their positions.
109% more call options, than puts
Call options by funds: $96.8M | Put options by funds: $46.3M
56% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 45
0.26% more ownership
Funds ownership: 30.22% → 30.48% (+0.26%)
4% less funds holding
Funds holding: 191 → 184 (-7)
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
40% less capital invested
Capital invested by funds: $895M → $533M (-$362M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$37.2M |
| 2 |
Renaissance Technologies
New York
|
+$19M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$13.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.2M |
| 5 |
Millennium Management
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$33.2M |
| 2 |
Morgan Stanley
New York
|
-$26.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.7M |
| 4 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$21M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$20.1M |
AUPH Hedge Fund Activity: Q1 2022 in Review
184 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2022, worth a combined $533M — down 40% from $895M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of AUPH and 33 opened new positions — a net loss of 6 holders — while 45 trimmed existing stakes and 70 added.
The largest buyer was Bellevue Group, opening a new position worth an estimated $37.2M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $33.2M sold.
- 184 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2022, down from 191 in Q4 2021.
- Funds reported $533M of Aurinia Pharmaceuticals stock for Q1 2022, down 40% quarter-over-quarter.
- 33 funds opened new Aurinia Pharmaceuticals positions in Q1 2022 and 39 closed out, a net change of -6 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2022 was Bellevue Group, an estimated $37.2M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $33.2M sold.
Based on aggregated 13F filings for Q1 2022.